Oct 14, 2015_Bone and Mineral Metabolism PR

Related Posts

• NEPHROLOGISTS PERCEIVE THE ANEMIA EFFECTS OF KERYX’S AURYXIA TO BE FAVORABLE, BUT MARKET PENETRATION AT SIX MONTHS POST LAUNCH IS LOW

  Familiarity with Auryxia is the primary barrier to adoption and growth, according to Spherix Global Insights, GmbH August 20, 2015…

• RealTime Dynamix™: Renal Anemia, June 2016

  Monthly report covering the dialysis and chronic kidney disease market for ESAs and IV Iron.  Additional insight on the development…

• In the Race for Alternative MOA Biologic in Crohn’s Disease, Takeda’s Entyvio Maintains the Lead, but Janssen’s Stelara is Gaining Fast

  Not only has Stelara's user-base substantially increased since Q1, but US gastroenterologists (n=103) are projecting significant gains for the IL-12/23…